Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

at this first dose tested in the Phase Ib study," commented James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We believe this early data continues to position ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV and we look forward to investigating ANA598 in longer-term studies in combination with current standard of care."

"The clinical and preclinical profile of ANA598 observed to date is very impressive," said Steve Worland, Ph.D., President and CEO of Anadys. "The magnitude of viral load drop reported today for ANA598 is greater than has been reported for any other non-nucleoside HCV inhibitor in a monotherapy study. Furthermore, the rate of initial viral load decline, believed to be associated with direct inhibition of viral replication, is greater than has been reported previously for all classes of HCV polymerase inhibitors, including nucleosides. This demonstrated antiviral potency holds significant promise for the future use of ANA598 in combination with other anti-HCV agents."

About ANA598

Anadys retains worldwide rights to ANA598, which was fully discovered at the Company. Preclinical evaluation of ANA598 was completed in the first quarter of 2008, leading to submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA), subsequent allowance of the IND by the FDA and initiation of clinical investigation in the second quarter of 2008. In December 2008, Anadys announced that the FDA granted fast track designation to ANA598 for the treatment of chronic HCV.

In October 2008, Anadys initiated patient dosing in the Phase Ib study of ANA598 in HCV patients. In the double-blind, randomized placebo-controlled Phase Ib study, treatment-naive genotype 1a and 1b patients are to receive oral capsules of ANA598 over three days at doses of 200 mg bid (twice
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 29, 2014 Electrodes are devices that ... be amplified to diagnose as well as treat ... medical devices facilitate the detection of chemical reactions ... and neurons of the patients. In addition, few ... alternating current to perform minimally invasive surgical procedures. ...
(Date:10/30/2014)... 29, 2014 Hospital stretchers are apparatus ... to another, inside or outside of medical infrastructure ... are also used for several specialized functions such ... emergency platforms. The hospital stretchers market ... future market potential of hospital stretchers globally. The ...
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli Lilly ... of its long-standing technology transfer program to increase the ... in 2003, the effort included Lilly donating manufacturing technology ... China , India ... South Africa – all MDR-TB ,hot spots., ...
Breaking Medicine Technology:Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4
(Date:10/30/2014)... (HealthDay News) -- When it comes to heart disease, a ... delay care when they have symptoms that spell trouble. ... hospital with a more severe or advanced stage of heart ... Catherine Kreatsoulas, a Fulbright Scholar and research fellow at the ... from the Heart and Stroke Foundation of Canada. In ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, ... bad for your health, a new study reports. Previous ... strengthen bones and prevent osteoporosis. These benefits to bone health ... of a healthy diet. But this new study found ... or women from bone fractures, and was linked to an ...
(Date:10/30/2014)... 2014 (HealthDay News) -- Americans, opinions about the Affordable ... new study finds. Democratic voters are strongly in ... the researchers. Almost three-quarters of Democrats want the next ... want Congress to implement the current law, while 44 ... Among Independent voters, one-third want the law repealed, ...
(Date:10/30/2014)... – A new standard of care for children facing ... multi-year study published in the latest edition of the ... research, led by John Wagner, Jr., M.D., director of ... University of Minnesota and a researcher in the Masonic ... with acute leukemia and myelodysplastic syndrome who received transplants ...
(Date:10/29/2014)... study has found that certain prostate cancer medications are ... causes in men with congestive heart failure or prior ... findings will help doctors and patients weigh the benefits ... therapy (ADT), which reduces levels of male hormones in ... is a mainstay of treatment for prostate cancer. Despite ...
Breaking Medicine News(10 mins):Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2
... month long fund raising events to find the cure, ... officially declared November as Tay-Sachs Awareness Month,and encourages all ... the need for research to help find a cure. ... frequently in Ashkenazi Jews, French,Canadians, Louisiana Cajuns, and Irish ...
... breakdown, in the epidermis , , FRIDAY, Nov. 2 (Health ... the biological mechanism by which stress increases susceptibility to ... the basis of the stress," said study author Dr. ... of California, San Francisco, and the VA Medical Center, ...
... Mammography Van Features ... NovationDR Digital System, MALVERN, Pa., Nov. 2 ... digital mammography,system in the U.S. The MAMMOMAT(R) NovationDR, a ... Nevada Cancer Institute,s,(NVCI) new Hope Coach, a mobile digital ...
... Emotional Intelligence could be defined as the capacity to perceive, ... so as to be able to distinguish between emotions and ... actions. One of the important benefits of developing this type ... with others and to face an ever changing social and ...
... LAUREL, N.J., Nov. 2 MedQuist Inc. (Pink,Sheets: MEDQ) ... its,previously-disclosed review of strategic alternatives for the Company, is,evaluating ... best interests of the,Company and its shareholders, in light ... ("Philips") of its decision to proceed,with the sale of ...
... Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today ... designation awarded to PI-88 for the,prevention of tumour ... in order to commence the Phase 3 program ... continue with the Special Protocol,Assessment process. The ...
Cached Medicine News:Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 2Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 3Health News:Stress Robs Skin of Antimicrobial Defenses 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 3Health News:Emotional Intelligence and the use of tobacco and cannabis 2Health News:MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 3
... a product comes along that forever raises ... category. The new StealthStation TREON plus Treatment ... Built on the phenomenal success of the ... system in the worldthe new TREON plus ...
... the DigiCat Imager ("DCI") to provide rapid, ... The DCI can measure the cataract and ... objective, appropriate and timely surgical decision can ... technology is especially useful in todays healthcare ...
... Until recently, most patients with age-related macular ... to improve or stabilize with or without ... Lumenis has revolutionized the standard of care ... the Opal Photoactivator especially for use in ...
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
Medicine Products: